Related Experiment Video

Updated: May 10, 2026

An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation
11:20

An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation

Published on: August 30, 2017

6.8K

A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1

Nicholas T Hertz1, Amandine Berthet, Martin L Sos

  • 1Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.

Cell
|August 20, 2013
PubMed

Insights

Researchers discovered a new way to boost the activity of PINK1, a key protein in Parkinson's disease (PD) pathogenesis. This novel neo-substrate approach using kinetin triphosphate (KTP) offers a potential therapeutic strategy for PD.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Mitochondrial Biology

Background:

  • Mitochondria play a crucial role in Parkinson's disease (PD) pathogenesis.
  • Mutations in the PTEN-induced kinase 1 (PINK1) gene are linked to early-onset PD and mitochondrial dysfunction.
  • Current therapeutic strategies for PD have not explored enhancing PINK1 activity due to the absence of known allosteric regulatory sites.

Purpose of the Study:

  • To investigate a novel therapeutic strategy for Parkinson's disease by enhancing PINK1 kinase activity.
  • To explore the potential of a neo-substrate approach to modulate PINK1 activity, including PD-related mutants.

Main Methods:

  • Utilized the ATP analog kinetin triphosphate (KTP) as a neo-substrate to modulate PINK1 activity.
  • Assessed the impact of KTP and its precursor, kinetin, on PINK1 activity in cellular models.
  • Quantified downstream effects including Parkin recruitment, mitochondrial motility, and apoptosis levels.

Main Results:

  • Kinetin triphosphate (KTP) successfully increased the activity of both wild-type (WT) and mutant (G309D) PINK1.
  • Application of kinetin to cells led to significant increases in PINK1 activity.
  • Observed biologically relevant outcomes including enhanced Parkin recruitment to depolarized mitochondria, reduced axonal mitochondrial motility, and decreased apoptosis.

Conclusions:

  • The neo-substrate approach represents a viable strategy for increasing PINK1 kinase activity.
  • Kinetin and KTP demonstrate potential as therapeutic agents for conditions involving PINK1 dysfunction, such as Parkinson's disease.
  • The discovery of neo-substrates opens new avenues for regulating kinase activity in various biological contexts.

More Related Videos

Multi-color Localization Microscopy of Single Membrane Proteins in Organelles of Live Mammalian Cells11:06

Multi-color Localization Microscopy of Single Membrane Proteins in Organelles of Live Mammalian Cells

Published on: June 30, 2018

8.1K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...